Navigation Links
CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies

LOS ANGELES--(BUSINESS WIRE)--Apr 4, 2007 - CytRx Corporation (NASDAQ:CYTR) today announced positive results of additional animal stroke studies indicating that CytRx's lead drug candidate arimoclomol significantly accelerated the recovery of sensory and motor function in an experimental rat model of stroke, even when treatment was withheld as long as 48 hours after stroke was induced. These data confirm and expand upon preclinical data announced by CytRx in December 2006. Orally-administered arimoclomol is currently in clinical evaluation as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Based on these impressive results, CytRx will begin planning a potential Phase II clinical trial with arimoclomol in stroke patients.

"These new animal results show that arimoclomol has the potential to help patients recover from the devastating effects of stroke even if the drug is administered well after the actual stroke event," said CytRx President and CEO Steven A. Kriegsman. "We believe this represents a unique advantage of arimoclomol compared with other stroke drug candidates. If efficacious in stroke patients, it would represent a major breakthrough in improving their quality of life. Furthermore, arimoclomol's flexibility for delayed intervention may allow substantial penetration into the $58 billion stroke market because the 'race' to get the patient to an emergency room for treatment may not significantly limit its use, unlike other potential stroke drugs."

In the present study, stroke was induced in rats by blocking blood flow to parts of the brain causing cerebral oxygen deprivation. The rats then received an oral dose of arimoclomol or control substance daily for 35 days, beginning either 6, 12, 24 or 48 hours after stroke was induced. Recovery from stroke was measured by monitoring sensory motor skills. While motor skills declined dramatically in all study rats i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
3. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Havel,s market leading EchoStim® Echogenic Insulated needle has ... Peripheral Nerve Blocks (PNBs) using nerve stimulation and ... improved needle has more, brighter, easier to see ... inexperienced practitioners the benefits of using both nerve ...
... 12, 2011 The association representing Montana,s providers of ... bill in Congress to repeal the controversial Medicare "competitive" ... "It is imperative that H.R. 1041 pass ... Medicare patients and local businesses in Montana," said Mike ...
Cached Medicine Technology:Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 2Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 3Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 4
(Date:4/23/2014)... Cancer Center researchers say clinical trials for a ... (AML) are very promising. Patients treated with CPX-351, ... daunorubicin, are showing better responses than patients treated ... , "Acute myeloid leukemia is an aggressive blood ... especially in older patients," explained Jeffrey Lancet, M.D., ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... that targets an important brain receptor has a dramatic ... relapse behavior, a University at Buffalo animal study has ... may be a novel lead compound for treating cocaine ... research was published as an online preview article in ... the compound, RO5263397, severely blunted a broad range of ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... Management Team and Board of Directors , ... Company,s VisionCHERRY HILL, N.J., March 18 eFoodSafety.com, Inc. ... company with a portfolio of aesthetic, dermatology, environmental and ... name from eFoodSafety.com, Inc. to Nuvilex, Inc. The Company ...
... software provider , is launching a new website. The website ... in-depth understanding of EMR-integrated services Also featured are an email ... , ... Little Rock, AR (PRWeb) March 18, 2009 ...
... EXTON, Pa., March 18 Kensey Nash Corporation (Nasdaq: ... has approved a stock repurchase. The new program allows ... of its issued and outstanding shares of Common Stock and ... the repurchases using its available cash. "Given our strong cash ...
... YORK, March 18 The Dirty Secrets ... products labeled "fragrance free" may actually contain chemicals to ... pollute the air in your home with harmful chemicals. ... about common spring cleaning hazards and how to avoid ...
... SAN FRANCISCO, March 18 The Women,s Dermatologic ... announces the 2009-2010 presidency of Wendy E. Roberts, ... Annual Meeting Luncheon held recently in conjunction with the ... Suzanne M. Connolly, MD , served as WDS ...
... Patient,s Own Stem Cells to Be Harvested and Transplanted ... Permanent Dental ImplantationRANCHO SANTA MARGARITA, Calif., March 18 ... infectious grin, but to attach an implant would be ... in his jaw. Dr. Ivan Ho, a Southern ...
Cached Medicine News:Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 2Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 3Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 4Health News:New Electronic Medical Transcription Company Website Arrives 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:Five Hot Show Ideas for Spring-Related Topics 2Health News:Wendy E. Roberts, MD, Named 2009-2010 President of the Women's Dermatologic Society 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 3
... Portex® Blue Line ULTRA® Suctionaid® tracheostomy tubes ... removal of secretions from above the tracheostomy ... ULTRA® Suctionaid® tracheostomy tubes provide an additional ... from above the tracheostomy tube cuff helping ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
... For additional patient safety, the ... an integral 15 mm ISO ... to a ventilator, with or ... place , ,Portex® laryngectomy ...
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
Medicine Products: